top of page

Free Biopharma Daily Stock Updates - 11/30/21

$XBI $116.27 +1.06%

 


Covid Updates

$


Pipeline Updates

$SRRK +4.1% Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) source


$LGVN 0.0% Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients source


$CDAK +1.8% Codiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing Expected 1H 2022 source


$ALZN -3.6% Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s source


$JAZZ -2.1% Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer source


$LCTX +12.7% Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen® source


$HEPA +1.6% Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH source


$KYMR +3.0% Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413 source


$EVFM +3.3% Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate source


$JAZZ -2.1% Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca™ (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade source


$TGTX -34.9% TG Therapeutics Provides Regulatory Update source


$IMV -2.6% IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer source


$ARDX +32.2% Ardelyx Launching IBSRELA® Second Quarter of 2022 source


$MCRB +22.0% SERES THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 1B STUDY OF SER-155, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC TO REDUCE THE RISK OF ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS AND GRAFT-VERSUS-HOST DISEASE (GVHD) source


$OLMA -60.1% Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer source


$TALS -4.9% Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma source


$IMGN -29.9% ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer source


$FENC -8.2% FENNEC PHARMACEUTICALS RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR ITS NEW DRUG APPLICATION FOR PEDMARK™ TO PREVENT OTOTOXICITY ASSOCIATED WITH CISPLATIN IN PEDIATRIC PATIENTS WITH LOCALIZED, NON-METASTATIC, SOLID TUMORS source


$ATHX +3.9% Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine source



Business Updates

$IMGN +29.89% ImmunoGen Announces Proposed Public Offering of Common Stock source

 

Posted by JM

0 comments

Comments


bottom of page